FluMist, the alternative to the injectable flu shot, will likely be in short supply this year, according to STAT.
The nasal spray's maker, AstraZeneca, has shipped only three lots, or about 758,000 doses, to the U.S. market, which is a fraction of what it supplied in earlier seasons.
AstraZeneca said the short supply resulted from difficulty producing viruses needed for two of the four components of the vaccine.
Read more here.